rytelo
(imetelstat sodium)Geron Corporation
Usage: RYTELO is indicated for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia (requiring 4+ red blood cell units over 8 weeks) and have not responded to or are ineligible for erythropoiesis-stimulating agents (ESA).